Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit - The Linz Intensive Care Unit (LICU) study

Clinica Chimica Acta

Volumn 413, Issue 5-6, 2012, Pages 587-593

  Dieplinger, Benjamin ^a   Egger, Margot ^a   Koehler, Wolfgang ^a   Firlinger, Fritz ^a   Poelz, Werner ^b   Lenz, Kurt ^a   Haltmayer, Meinhard ^a   Mueller, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Cytokines; Interleukin 33; Natriuretic peptide; Procalcitonin; Prognosis; Troponin

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; INTERLEUKIN 6; PROCALCITONIN; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; APACHE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIMPLIFIED ACUTE PHYSIOLOGY SCORE II; SURVIVOR;

AGED; AGED, 80 AND OVER; AUSTRIA; COHORT STUDIES; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; SOLUBILITY;

EID: 84856218846     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.028     Document Type: Article

References (35)

1. Iwahana H., Yanagisawa K., Ito-Kosaka A., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264:397-406.
2. Bergers G., Reikerstorfer A., Braselmann S., et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13:1176-1188.
3. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
4. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
5. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
6. Shimpo M., Morrow D.A., Weinberg E.O., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190.
7. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
8. Rehman S.U., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008, 52:1458-1465.
9. Miller A.M., Liew F.Y. The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease. Pharmacol Ther 2011, 131:179-186.
10. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
11. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage™ ST2 assay. Clin Chim Acta 2009, 409:33-40.
12. Dieplinger B., Gegenhuber A., Kaar G., et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010, 43:714-719.
13. Socrates T., deFilippi C., Reichlin T., et al. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 2010, 268:493-500.
14. Shah K.B., Kop W.J., Christenson R.H., et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 2011, 57:874-882.
15. Lloyd C.M. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol 2010, 22:800-806.
16. Hacker S., Lambers C., Pollreisz A., et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 2009, 23:372-379.
17. Oshikawa K., Kuroiwa K., Tago K., et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001, 164:277-281.
18. Brunner M., Krenn C., Roth G., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004, 30:1468-1473.
19. Hoogerwerf J.J., Tanck M.W., van Zoelen M.A., et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010, 36:630-637.
20. Alves-Filho J.C., SÔnego F., Souto F.O., et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nature Med 2010, 16:708-712.
21. Wagenaar J.F., Gasem M.H., Goris M.G., et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl Trop Dis 2009, 3:e453.
22. Becerra A., Warke R.V., de Bosch N., et al. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008, 41:114-120.
23. Roth G.A., Zimmermann M., Lubsczyk B.A., et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J Surg Res 2010, 163:e79-e83.
24. Talabot-Ayer D., McKee T., Gindre P., et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 2011, doi:10.1016/j.jbspin.2011.02.011 [Epub ahead of print].
25. Mok M.Y., Huang F.P., Ip W.K., et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010, 49:520-527.
26. Knaus W.A., Wagner D.P., Draper E.A., Zimmerman J.E., Bergner M., Bastos P.G., Sirio C.A., Murphy D.J., Lotring T., Damiano A. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-1636.
27. Knaus W.A., Draper E.A., Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
28. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
29. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
30. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117:1936-1944.
31. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008, 14:732-738.
32. Oboki K., Ohno T., Kajiwara N., et al. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010, 59:143-160.
33. Oboki K., Ohno T., Kajiwara N., et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010, 107:18581-18586.
34. Mildner M., Storka A., Lichtenauer M., et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 2010, 87:769-777.
35. Afessa B., Gajic O., Keegan M.T. Severity of illness and organ failure assessment in adult intensive care units. Crit Care Clin 2007, 23:639-658.